Loading clinical trials...
Loading clinical trials...
Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock. A Randomized, Double-blind, Placebo Controlled Dose Selection Study
Conditions
Interventions
nangibotide low dose
nangibotide high dose
+1 more
Locations
43
Belgium
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Ziekenhuis Oost-Limburg
Genk, Belgium
UZ Gent
Ghent, Belgium
Centre hospitalier Jolimont-Lobbes
La Louvière, Belgium
CHU Marie Curie
Lodelinsart, Belgium
Clinique Saint-Pierre
Ottignies, Belgium
Start Date
November 13, 2019
Primary Completion Date
May 9, 2022
Completion Date
May 9, 2023
Last Updated
April 11, 2023
NCT06155812
NCT06043505
NCT05688774
NCT04569942
NCT06727318
NCT02664753
Lead Sponsor
Inotrem
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions